Keith T Flaherty on Muck Rack

Keith T Flaherty

As seen in: Cancer Research, Nature, Taylor & Francis Online, JAMA Dermatology, Cell Press, Cell Reports Medicine, The Lancet, Annals of Internal Medicine, Healio, HemOnc Today, Cancer Discovery and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Keith T

Contact Keith T, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma

|
By Shiyou Wei, Yulan Deng, Jinho Lee, Hongbin Lan, Zhenyu Yang, Marilyne Labrie, Courtney B. Betts, Hao Duan, Benjamin Tate, Joanna Pucilowska, Dennie T. Frederick, Aleigha Lawless, Tatyana Sharova, Yuanzhong Yang, Wanming Hu, Georgia Beasley, Lynn M. Schuchter, Xiuqi Wang, Wei Xu, Megan Vandenberg, Drew Torigian, Shamilene Sivagnanam, Kuang Du, Eric Sugarman, Suzanne McGettigan, Cathy Zheng, Rami N. Al-Rohil, Michael Datto, Giselle Y. López, Smita Nair, David Ashley, Xiaowei Xu, Ravi K. Amaravadi, Giorgos C. Karakousis, Donald M O'Rourke, Steven Brem, Bert W O'Malley, Gokhan Demirkan, Shuangxing Yu, Yiling Lu, Todd Camp, Janice Patterson, Zhi Wei, Christopher L. Corless, Dmitry I Gabrilovich, Yonggao Mou, Keith T Flaherty, Lisa M. Coussens, Genevieve M. Boland, Meenhard Herlyn, Gordon Mills, Lunxu Liu, Gao Zhang, Maria A. Selim
| Cell Reports Medicine
Keywords melanoma immune checkpoint blockade resistance dynamic evolution Introduction In 2022, there were approximately 330,000 newly diagnosed primary cutaneous melanoma cases and 58,645 deaths related to melanoma worldwide.1 Over the past decade, systemic therapies have significantly improved outcomes for advanced or metastatic melanoma.
Open in Who Shared Issue with article?

Facts and Hopes: Toward the Next Quantum Leap in Melanoma

|
By Keith T Flaherty
| Texas Medical Center
Clinical Cancer Research 10.1158/1078-0432.CCR-25-0278 Author MSS Humans, Melanoma, Immunotherapy, Immune Checkpoint Inhibitors, Molecular Targeted Therapy, Skin Neoplasms yes Flaherty, Keith T; Aplin, Andrew E; Davies, Michael A; et al., "Facts and Hopes: Toward the Next Quantum Leap in Melanoma" (2025). Faculty, Staff and Student Publications. 5507. https://digitalcommons.library.tmc.edu/uthgsbs_docs/5507
Open in Who Shared Issue with article?

Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death

|
By M. Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, John P. Plastaras, Jianhua Ling, Wenge Wang, Zhaoyu Jin, Yingqiu Liu, David T. Dicker, Paul Chiao, Keith T Flaherty, Charles Smith, Wafik El-Deiry
| Cell Press
Main text (Cancer Cell 12, 66–80; July 2007) This publication demonstrated that cells expressing oncogenic are sensitized to TRAIL-induced apoptosis, and that the combination of TRAIL with sorafenib further enhances this sensitivity. We, the authors, were made aware of errors in the figures. The top panel (RelA/p65) in Figure 4E was duplicated from the top left panel (p65/RelA) in Figure 5H. Additionally, the IgG panel for Mcl-1 in Figure 4E was incorrectly placed.
Open in Who Shared Issue with article?
See all 48 licensed articles (58 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Keith T

Contact Keith T, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified